Seattle Genetics shares rise on strong Adcetris sales, $218M in revenue for Q2 Cancer drugmaker Seattle Genetics reported stronger-than-expected revenues for the second quarter as its stock rose more than 8 percent in… Read More
Seattle Genetics drug rides FDA fast-track to the front lines in fight against rare form of cancer Seattle Genetics’ star cancer drug Adcetris has won Food and Drug Administration approval for treatment of a fast-growing type of… Read More
